References
1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G.
Oral anticoagulant therapy - Antithrombotic therapy and prevention of
thrombosis, 9th ed: American College of Chest Physicians evidence-based
clinical practice guidelines. Chest . 2012;141(2
SUPPL.):e44S-e88S. doi:10.1378/chest.11-2292
2. Huisman M V., Rothman KJ, Paquette M, et al. Antithrombotic treatment
patterns in patients with newly diagnosed nonvalvular atrial
fibrillation: The GLORIA-AF Registry, phase II. Am J Med .
2015;128(12):1306-1313.e1. doi:10.1016/j.amjmed.2015.07.013
3. Adelborg K, Grove EL, Sundbøll J, Laursen M, Schmidt M. Sixteen-year
nationwide trends in antithrombotic drug use in Denmark and its
correlation with landmark studies. Heart . 2016;102(23):1883-1889.
doi:10.1136/heartjnl-2016-309402
4. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of
warfarin and its drug and food interactions. Arch Intern Med .
2005;165(10):1095-1106. doi:10.1001/archinte.165.10.1095
5. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with
lipid-lowering drugs: Mechanisms and clinical relevance. Clin
Pharmacol Ther . 2006;80(6):565-581. doi:10.1016/j.clpt.2006.09.003
6. Hellfritzsch M, Lund LC, Ennis Z, et al. Ischemic Stroke and Systemic
Embolism in Warfarin Users With Atrial Fibrillation or Heart Valve
Replacement Exposed to Dicloxacillin or Flucloxacillin. Clin
Pharmacol Ther . 2020. doi:10.1002/cpt.1662
7. Kamali F, Hickmott H, Wynne H. The effect of simvastatin
co-medication on warfarin anticoagulation response and dose
requirements. Thromb Haemost . 2003;89(5):949-950.
doi:10.1055/s-0037-1613486
8. Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB. The effect of
converting from pravastatin to simvastatin on the pharmacodynamics of
warfarin. J Clin Pharmacol . 1999;39(1):86-90.
doi:10.1177/00912709922007598
9. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck
DW. Effect of rosuvastatin on warfarin pharmacodynamics and
pharmacokinetics. J Clin Pharmacol . 2005;45(8):927-934.
doi:10.1177/0091270005278224
10. Andersson ML, Mannheimer B, Lindh JD. The effect of simvastatin on
warfarin anticoagulation: a Swedish register-based nationwide cohort
study. Eur J Clin Pharmacol . 2019;75(10):1387-1392.
doi:10.1007/s00228-019-02703-3
11. Stern, Abel, Gibson L. Atorvastatin Anticoagulant. J Clin
Pharmacol . 1997;37:1062-1064.
12. Jindal D, Tandon M, Sharma S, Pillai KK. Pharmacodynamic evaluation
of warfarin and rosuvastatin co-administration in healthy subjects.Eur J Clin Pharmacol . 2005;61(9):621-625.
doi:10.1007/s00228-005-0986-6
13. Lexicomp® Drug Interactions - UpToDate.
https://www.uptodate.com/drug-interactions/?source=responsive_home#di-document.
Accessed January 28, 2020.
14. Drug Interactions search - MICROMEDEX.
https://www.micromedexsolutions.com/micromedex2/librarian/CS/DFE440/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/A7EB49/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.FindDrugInteractions?navitem=topInteractions&isToolPage=true.
Accessed January 28, 2020.
15. Interaktionsdatabasen.dk. http://www.interaktionsdatabasen.dk/.
Accessed January 29, 2020.
16. The Copenhagen Primary Care Laboratory Database.
https://publichealth.ku.dk/research/databases-for-collaboration/coplab/.
Accessed April 1, 2020.
17. Medici BB, Nygaard B, La Cour JL, et al. Changes in Prescription
Routines for Treating Hypothyroidism between 2001 and 2015: An
Observational Study of 929,684 Primary Care Patients in Copenhagen.Thyroid . 2019;29(7):910-919. doi:10.1089/thy.2018.0539
18. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas
J, Schmidt M. Data resource profile: The Danish national prescription
registry. Int J Epidemiol . 2017;46(3):798. doi:10.1093/ije/dyw213
19. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L,
Sørensen HT. The Danish National patient registry: A review of content,
data quality, and research potential. Clin Epidemiol .
2015;7:449-490. doi:10.2147/CLEP.S91125
20. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration
System as a tool in epidemiology. Eur J Epidemiol .
2014;29(8):541-549. doi:10.1007/s10654-014-9930-3
21. Keeling DM, Baglin T, Tait C, et al. Guidelines on oral
anticoagulation with warfarin - fourth edition. Br J Haematol .
2011;154(3):311-324. doi:10.1111/j.1365-2141.2011.08753.x
22. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic
and thrombolytic therapy for valvular disease: Antithrombotic therapy
and prevention of thrombosis, 9th ed: American college of chest
physicians evidence-based clinical practice guidelines. Chest .
2012;141(2 SUPPL.):e576S-e600S. doi:10.1378/chest.11-2305
23. Nielsen SF, Nordestgaard BG. Negative statin-related news stories
decrease statin persistence and increase myocardial infarction and
cardiovascular mortality: A nationwide prospective cohort study.Eur Heart J . 2016;37(11):908-916. doi:10.1093/eurheartj/ehv641
24. Schmidt M, Hallas J, Laursen M, Friis S. Data Resource Profile:
Danish online drug use statistics (MEDSTAT). Int J Epidemiol .
2016;45(5):1401-1402G. doi:10.1093/ije/dyw116
25. Medstat. https://medstat.dk/. Accessed March 27, 2020.
26. Nelson WW, Wang L, Baser O, Damaraju C V., Schein JR. Out-of-range
INR values and outcomes among new warfarin patients with non-valvular
atrial fibrillation. Int J Clin Pharm . 2014;37(1):53-59.
doi:10.1007/s11096-014-0038-3
27. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and
prediction of adverse events in patients with atrial fibrillation: A
systematic review. Circ Cardiovasc Qual Outcomes .
2008;1(2):84-91. doi:10.1161/CIRCOUTCOMES.108.796185
28. Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S.
Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal
Bleeding Risk. Am J Med . 2010;123(2):151-157.
doi:10.1016/j.amjmed.2009.07.020
29. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the
antifungal agents on oxidative drug metabolism. Clinical relevance.Clin Pharmacokinet . 2000. doi:10.2165/00003088-200038020-00002